Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 2 1

Status

Completed 3

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

CNS 3Sarcoma 2

Conditions

Carcinoma, Non-Small-Cell Lung 8Neoplasms 4Lung Neoplasms 4Glioma 4Neoplasm Metastasis 3Glioblastoma 3Colorectal Neoplasms 3Brain Neoplasms 3Pancreatic Neoplasms 2Head and Neck Neoplasms 2Gliosarcoma 2Esophageal Neoplasms 2Carcinoma, Medullary 2Breast Neoplasms 2Adenocarcinoma 2Waldenstrom Macroglobulinemia 1Unspecified Adult Solid Tumor, Protocol Specific 1Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1Thyroid Cancer, Papillary 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Sezary Syndrome 1Salivary Gland Neoplasms 1Recurrence 1Rectal Neoplasms 1Prostatic Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pheochromocytoma 1

Interventions

Temozolomide 38Radiotherapy 22Radiosurgery 22Radiation 11Magnetic Resonance Spectroscopy 11Irinotecan 11Cyclophosphamide 11Etoposide 10Surgical Procedures, Operative 9Erlotinib Hydrochloride 9Carmustine 9pembrolizumab 8Filgrastim 8Carboplatin 8Bevacizumab 7Vincristine 6Sorafenib 6O(6)-benzylguanine 6Nivolumab 6Flucytosine 6Aminolevulinic Acid 6temsirolimus 5sargramostim 5Vorinostat 5Trastuzumab 5Topotecan 5Lomustine 5Imatinib Mesylate 5Granulocyte Colony-Stimulating Factor 5Everolimus 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × Brain Neoplasms × vandetanib × Clear all
NCT00272350 2019-12-05

ZD6474 to Treat Advanced Brain Cancer in Patients

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
83 enrolled
CNS

Brain Neoplasms, Glioma, Neoplasms, Disease Progression

NCT00613223 2013-02-20

Ph I Dose Escalation Trial of Vandetanib in Combo w Etoposide for Malignant Gliomas

Duke University

Phase 1 Completed
49 enrolled
CNSSarcoma

Brain Neoplasms, Glioblastoma, Glioma, Gliosarcoma

NCT00613054 2012-12-05

Ph I Zactima + Imatinib Mesylate & Hydroxyurea for Pts w Recurrent Malignant Glioma

Duke University

Phase 1 Completed
27 enrolled
CNSSarcoma

Brain Neoplasms, Glioblastoma, Glioma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡